Research programme: Ebola therapeutics - Intellimedix
Latest Information Update: 20 Oct 2014
At a glance
- Originator Intellimedix
- Developer Georgia Institute of Technology; Intellimedix
- Mechanism of Action Protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Ebola virus infections
Most Recent Events
- 16 Oct 2014 Early research in Ebola virus infections in USA (unspecified route)